Sionna Therapeutics, Inc. cotiza a 4.69 USD y tiene una capitalización bursátil de $212M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; na…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.66 | $-0.60 | $-0.46 |
| Estimado | $-0.68 | $-0.65 | $-0.50 | $-0.53 |
| Sorpresa | — | -1.5% | -20.0% | +13.2% |
| Métrica | SION | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -24.5% | -40.4% | +15.9% |
| ROA | -23.1% | -32.0% | +8.9% |
| Current Ratio | 20.61 | 2.84 | +17.77 |
| Debt / Equity | — | 0.28 | — |